<DOC>
	<DOCNO>NCT02766868</DOCNO>
	<brief_summary>Patients refractory relapse lymphoblastic leukemia poor outcome even marrow ablative conditioning mostly standard iv-Bu-Cy Cy-TBI . In study , focus new treatment strategy high-dose chemotherapy regimen consist fludaraibine+cytarabine+cyclophosphamide+etoposide follow reduced intensity condiotning regimen consist fludarabine , busulfan post-infusion cyclophophamide .</brief_summary>
	<brief_title>Sequential Intensive Chemotherapy Followed RIC Refractory Relapse ALL</brief_title>
	<detailed_description>All patient refractory relapse lymphoblastic leukemia receive high-dose chemotherapy regimen consist fludaraibine+cytarabine+ cyclophosphamide+etoposide . At day 7 chemo , bone marrow aspiration MRD study flow-cytometry plan . For patient residual blast undergo allogeneic stem cell transplantation reduce intensity condiotning regimen consist 5-day fludarabine 3-day busulfan post-infusion cyclophophamide ( D+3 +4 ) GVHD prophylaxis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>adult patient refractory relapse acute lymphoblastic leukemia remission 2 cycle induction chemotherapy early relapse ( 1st remission less 6 month ) remission 1 cycle reinduction chemotherapy multiple relapse age 1660 year inform consent contraindication allogeneic transplantation : active infection , allergy FLu/Bu/CTX , liver renal function damage HLA match relate ( 6/6 ) , unrelated donor ( 8~10/10 ) haplo liver function/renal function damage ( 2 X upper normal range ) mental disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>